New combo aims to boost lung cancer treatment
NCT ID NCT03991819
First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This early-phase trial is testing whether adding the experimental drug binimetinib to the immunotherapy pembrolizumab (Keytruda) helps people with advanced non-small cell lung cancer. About 40 participants with high PD-L1 levels will receive the combination. The study aims to find the best dose and check if the treatment is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allan Blair Cancer Centre
RECRUITINGRegina, Saskatchewan, S4T 7T1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITINGCalgary, Alberta, T2N 4N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Saskatoon Cancer Centre
RECRUITINGSaskatoon, Saskatchewan, S7N 4H4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
binimetinib and pembrolizumab (Keytruda)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced non-small cell lung cancer who have high PD-L1 levels.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.